Free tool
FAERS Monitor: Treanda
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022303 or its brand name (Treanda, Bendamustine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
11,430
Serious
9,922
87% of reports
Hospitalization
4,450
Death reported
2,006
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,082
- pyrexia842
- disease progression569
- febrile neutropenia522
- rash516
- neutropenia487
- pneumonia458
- drug ineffective438
- platelet count decreased435
- neutrophil count decreased418
- product use in unapproved indication411
- covid-19406
- anaemia391
- pancytopenia380
- malignant neoplasm progression379
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 56 |
| 2009 | 180 |
| 2010 | 293 |
| 2011 | 278 |
| 2012 | 1,407 |
| 2013 | 512 |
| 2014 | 473 |
| 2015 | 628 |
| 2016 | 554 |
| 2017 | 534 |
| 2018 | 683 |
| 2019 | 640 |
| 2020 | 654 |
| 2021 | 752 |
| 2022 | 1,463 |
| 2023 | 1,034 |
| 2024 | 755 |
| 2025 | 301 |
| 2026 | 233 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,729 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neutrophil count decreasedSignal | 418 | 19.1 | 17.3 | 7,074 |
| febrile neutropeniaSignal | 522 | 14.6 | 13.4 | 6,562 |
| pancytopeniaSignal | 380 | 12.6 | 11.4 | 4,026 |
| disease progressionSignal | 569 | 8.9 | 8.2 | 3,978 |
| platelet count decreasedSignal | 435 | 7.5 | 6.9 | 2,462 |
| malignant neoplasm progressionSignal | 379 | 6.8 | 6.2 | 1,883 |
| neutropeniaSignal | 487 | 6.6 | 6.1 | 2,320 |
| pyrexiaSignal | 842 | 4.5 | 4.2 | 2,310 |
| covid-19Signal | 406 | 4.3 | 3.9 | 1,018 |
| anaemiaSignal | 391 | 3.8 | 3.4 | 802 |
| product use in unapproved indicationSignal | 411 | 3.1 | 2.8 | 572 |
| pneumoniaSignal | 458 | 2.6 | 2.4 | 458 |
| off label useSignal | 1,082 | 2.3 | 2.1 | 805 |
| rashSignal | 516 | 2.2 | 2.0 | 335 |
| drug ineffective | 438 | 0.6 | 0.6 | 115 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.